Claire Quigley

Claire Quigley

Auto-generated profile, based on publicly available information

Claire Quigley

Department of Dermatology Tallaght University Hospital Dublin Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Clinical and Experimental Dermatology
Verified
Journal Article
Open access
PDF file
LYLi Jie Helena Yoo
Li Jie Helena Yoo
SBStephanie Bowe
Stephanie Bowe
CQClaire Quigley
Claire Quigley
LVLiana Victory
Liana Victory
CDCiara Devenney
Ciara Devenney
PLPatsy Lenane
Patsy Lenane
The Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) is a tool that can be used to decide when to first screen for skin cancer in organ transplant recipients (OTRs). The objective of this study was to assess the applicability of this tool in thoracic OTRs. Based on data from patient files, the OTRs were categorized into four risk groups according to the SUNTRAC tool. The time of the first post-transplant skin cancer in each OTR was recorded. The proportion of OTRs with post-transplant skin cancer in the low-, medium-, high- and very high-risk groups was 0%, 28.3%, 58.3% and 100%, respectively. This positive correlation suggests that SUNTRAC can be used to determine when to first screen for skin cancer in heart and lung OTRs.

15 April 2025 in JEADV Clinical Practice
Verified
Journal Article
Open access
LYLi Jie Helena Yoo
Li Jie Helena Yoo
GMGregg Murray
Gregg Murray
CQClaire Quigley
Claire Quigley
FLFei Ya Lai
Fei Ya Lai
CJClaudine Howard James
Claudine Howard James
ATAnne‐Marie Tobin
Anne‐Marie Tobin

3 January 2022 in Our Dermatology Online
Verified
Journal Article
Closed access
CQClaire Quigley
Claire Quigley
SRSiona Ni Raghallaigh
Siona Ni Raghallaigh
Basal cell carcinomas (BCCs) are among the most common non-melanoma skin cancers in the world. However, given their slowly progressive nature, metastatic BCCs are a relatively uncommon entity. Below, we discuss two separate cases of metastatic BCC that we encountered in our clinical practice. The first is the case of a 57-year-old male with a right cheek BCC and bilateral pulmonary metastases. The second is the case of a 71-year-old male who also presented with a right BCC and pulmonary metastases. We discuss their altered clinical courses. We also conducted a review of the literature focusing on the use of the relatively novel hedgehog inhibitors as a treatment option for individuals diagnosed with metastatic BCC.

11 December 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
CQClaire Quigley
Claire Quigley
ESEoin R. Storan
Eoin R. Storan

14 October 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
CQClaire Quigley
Claire Quigley
CHClaudine Howard-James
Claudine Howard-James
HYHelena Yhoo
Helena Yhoo
FLFei Lai
Fei Lai
JYJiFung Yong
JiFung Yong
GMGregg Murray
Gregg Murray
We conducted informal and formal trend analysis on the term ‘sunbed’ assessing its search popularity, identifying the top-three social media (SM) sites where the term is mentioned, characterizing the persons or groups most likely to post about sunbeds and analysing the content that is most frequently being made available in relation to sunbeds. We found a statistically significant increase in the search trend for the term ‘sunbed’ between 2008 and 2023. While Instagram had the most sunbed mentions, TikTok videos had more viewer engagement. TikTok had more influencer-driven sunbed posts than the other SM platforms. Commercial premises posting about sunbed use featured heavily on Instagram (56%) and TikTok (40%). Our study highlights the harmful influence SM can have.

28 May 2025 in JEADV Clinical Practice
Verified
Journal Article
Open access
JYJi Fung Yong
Ji Fung Yong
FLFei Lai
Fei Lai
CQClaire Quigley
Claire Quigley
LYLi Jie Helena Yoo
Li Jie Helena Yoo
CHClaudine Howard‐James
Claudine Howard‐James
ATAnne‐Marie Tobin
Anne‐Marie Tobin
Background: Methotrexate, originally an anti‐neoplastic agent, is now extensively used at lower doses in dermatology and rheumatology for chronic inflammatory conditions. While its safety is supported by routine blood monitoring, there remains variability in recommended monitoring frequency, folic acid supplementation, liver function testing and the role of specific biomarkers like Type III Procollagen Peptide (PIIINP).Objectives: This study aimed to compare methotrexate prescribing and monitoring practices in Ireland with various national guidelines, including those from the European Medicines Agency (EMA), British Association of Dermatologists (BAD) and European Alliance of Associations for Rheumatology (EULAR). The goal was to document current practices among dermatologists and rheumatologists in Ireland to identify any discrepancies in methotrexate prescribing and monitoring.Methods: An online survey was distributed to members of the Irish Association of Dermatologists (IAD) and the Irish Society of Rheumatology (ISR) in July 2024. The questionnaire covered pretreatment screening, blood monitoring practices, folic acid supplementation and adverse events. Data was finalised and analysed in September 2024.Results: Of the 52 respondents, all conducted baseline full blood count (FBC), renal profile (RP) and liver function tests (LFTs). Dermatologists were significantly more likely to perform infectious disease screenings compared to rheumatologists (p < 0.05). When initiating methotrexate, only 17 practitioners (32.7%) employed a test dose of 2.5–5 mg weekly, with a statistically significant difference (p < 0.05) observed in the starting doses of methotrexate. All respondents prescribed folic acid supplementation, with a statistically significant (p < 0.05) noted in supplementation practices between the two specialties. Abnormal LFTs/PIIINP prompted hepatology referrals for 48%. Seven (13%) reported irreversible liver damage cases, and one (2%) death from pneumonia was noted.Conclusions: This study highlights significant discrepancies in methotrexate prescribing and monitoring practices among Irish clinicians, similar to the various international guidelines. These variations underscore the need for updated, unified guidelines to ensure consistent and safe methotrexate use across the specialties.